Valvular & structural heart diseaseCohort study
Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study
- Prospective single-arm postmarket registry
- open-label
- multicentre
- 26 sites in Europe
- central event adjudication
- echocardiographic core laboratory
Authors' conclusion
Tricuspid TEER using the TriClip system was safe and effective through 1 year for subjects with significant TR and advanced disease in a diverse real-world population.
Study context
- Population
- Patients with severe tricuspid regurgitation (TR) treated by tricuspid transcatheter edge-to-edge repair (TEER) in a real-world setting, Europe
- Participants
- 511 patients
- Outcome
- 1-year clinical outcomes
- Follow-up
- 1 year
Main finding
As reported in the abstract
TR reduced to moderate or less
81%
NYHA class I/II (baseline to 1 year)
21% to 75%, P < 0.0001
Kansas City Cardiomyopathy Questionnaire (KCCQ) score improvement
19 ± 26-point, P <0.0001
Observational data: associations, not effects.
Further findings
Predictors of 1-year mortality
| Comparison | OR (95% CI) | P value | |
|---|---|---|---|
| Baseline serum creatinine · independently associated with mortality | 2.169 (1.494–3.147) | P < 0.0001 | |
| Baseline RV TAPSE · independently associated with mortality | 0.636 (0.415–0.974) | P = 0.0375 | |
| 0.20.5125Odds ratio (log scale) |
Predictors of 1-year mortality
- 1-year mortality significantly lower with moderate or lower TR at 30 days; no difference among moderate, mild or trace TR
- Mortality not associated with baseline TR grade or center volume
Original publication
Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study. J Am Coll Cardiol. Published 15 May 2024. doi:10.1016/j.jacc.2024.05.006
Summarised from the published abstract; every number is checked against it